| Question |  |  | Expected Answers | Marks | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | (a) | (i) | Plasmodium; | 1 | Look for correct spelling of generic name but do not penalise the use of lower case initial letter. <br> We are not looking for specific name(s), so IGNORE species name. <br> So e.g.Plasmodium falciparum should be credited but NOT P. falciparum / P. vivax / P. ovale / P. malariae |
| 1 | (a) | (ii) | female Anopheles; | 1 | CREDIT phonetic spelling but genus must be correct |
| 1 | (a) | (iii) | hepatocyte / liver (cell) ; erythrocyte / red blood (cell) ; | 1 max | If a choice of answers is given do not credit unless both are valid. <br> DO NOT CREDIT 'RBC' as this is not a name |


| Question |  |  | Expected Answers | Marks | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | (b) | 1 <br> 2 <br> 3 <br> 4 <br> 5 <br> 6 <br> 7 <br> 8 <br> 9 <br> 10 <br> 11 <br> 12 <br> 13 <br> 14 | humoral response ; <br> (B) cell / lymphocy , <br> has antigen receptor / carries antibody on its surface ; <br> specific to / matches / complementary to, only one antigen ; <br> clonal selection ; <br> selection / activation , of , appropriate / specific , <br> B lymphocyte / B cell ; <br> by , macrophages / antigen presenting cells / dendritic cells / <br> T helper cells / cytokines / interleukins ; <br> clonal expansion ; <br> (selected cell) divides by mitosis / clones ; <br> (B) cel , differentiate / specialise ; <br> (B cells) form , plasma / effector , cells ; <br> (which) secrete / produce , antibodies; <br> antibodies are, specific / complementary, to antigen ; <br> (B cells) form memory cells ; <br> Either (memory cells) long-lived / remain in circulation / remain in body / provide immunological memory <br> or (provides) secondary response <br> or faster / stronger , response to subsequent exposure (of same antigen / pathogen / parasite) ; | 7 max | ACCEPT 'forms antigen-antibody complex' <br> DO NOT CREDIT ref to disease alone |
|  |  |  | QWC ~ correct sequence ; | 1 | Clonal selection, then clonal expansion, then differentiation (stages named or described) <br> Use the QWC tool to indicate these in the correct sequence and add 1 mark to the 7 max for content when all 3 stages have been addressed in the correct sequence. |


|  | ues | Expected Answers | Marks | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: |
| 1 | (c) | Assume that candidates are answering in terms of a person leaving the malarial area (unless otherwise stated). <br> no repeat infections / no further exposure (to antigen / pathogen / parasite) ; no booster / lose immunological memory ; <br> limited life for memory cells / numbers of memory cells reduce / memory cells lost ; so no , secondary response / secondary response described ; | 2 max | DO NOT CREDIT disease / malaria / bacterium / virus <br> CREDIT converse points if they answer the question in the context of a person staying in the malarial area. <br> e.g. repeat infections; <br> maintain immunological memory ; <br> memory cells present ; <br> secondary response available; |


| Quest | Expected Answers | Marks | Additional Guidance |
| :---: | :---: | :---: | :---: |
| (d) | different, strains / species / types (of Plasmodium) ; <br> different antigens; <br> due to , mutation / variation ; <br> more than one stage in the life cycle (within human) ; different stages have different antigens ; <br> so will need , a different vaccine / components of vaccine , for each , strain / stage ; <br> (parasite) concealed / hidden , in cells ; (parasite) only, exposed / in circulation , for short time ; <br> AVP; | 3 max | DO NOT CREDIT 'disease' or 'malaria' unqualified Max 2 if they think it is a virus / bacterium <br> 'different strains will require different vaccines' = 2 $\text { (mp } 1 \& 6 \text { ) }$ <br> CREDIT antigenic concealment <br> e.g. antigenic , shift / drift eukaryotes have greater capacity for variation antigens (on parasite) change over time when in human |
|  | Total | 16 |  |



| Question |  | Answer |  | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 2 | (c) | 1 2 3 | fossils show that organisms have changed over time ; <br> idea that fossils or rocks can be dated ; idea of fossils showing intermediate forms / sequences ; | 3 | 1 CREDIT many fossil organisms dissimilar from modern organisms <br> 2 ACCEPT idea of fossils in chronological order <br> 3 e.g. Archaeopteryx / Tiktaalik/ horse <br> 3 general trend from, small / simple, to, large / complex |
|  |  |  | Total | 8 |  |


| Question |  |  | Expected Answer | Mark | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 3 | (a) | (i) | genes / genetic / mutation ; <br> environment(al) ; | 2 | Mark the first answer on each line IGNORE inherited / DNA |
| 3 | (a) | (ii) <br> 1 <br> 2 <br> 3 <br> 4 | no defined categories ; <br> range of values / intermediate values; <br> influenced by, environment / many genes / genes and environment ; quantitative / has to be measured / cannot be counted; | 3 max | 2 ACCEPT ref to bell-shaped curve / binomial distribution <br> 3 ACCEPT any ref to 3 or more genes <br> 4 ACCEPT metric |
| 3 | (a) | (iii) | B ; | 1 | DO NOT CREDIT if more than one letter is given |
| 3 | (a) | (iv) <br> 1 <br> 2 <br> 3 <br> 4 | growth too rapid ; <br> increased susceptibility to, disease / named abnormality ; <br> inbreeding; <br> reduces gene pool / genetic variation / genetic diversity ; | 2 max | 2 e.g. bone / skeletal abnormalities or low immunity <br> 3 DO NOT CREDIT if implies inbreeding causes mutations <br> 4 IGNORE refs to biodiversity |


| Question |  |  | Expected Answer | Mark | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 3 | (a) | (v) 1 <br> 2 <br> 3 <br> 4 <br> 5 <br> 6 | maintain biodiversity ; <br> aesthetic (reasons) / tourism ; <br> ethical (reasons) ; <br> part of a food chain / web ; <br> maintain / increase gene pool ; <br> genetic resource / availability to breed with domestic chickens; | 2 max | 3 ACCEPT religious <br> 4 ACCEPT food source for local population <br> 6 CREDIT description, e.g. 'source of desirable genes' or 'source of genetic variation' <br> 6 ACCEPT specific example of genetic resource e.g. disease resistance / strong bones / longevity / heat tolerance / idea of domesticating wild population |


| Question |  |  | Expected Answer | Mark | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 3 | (b) | (i) <br> 1 <br> 2 <br> 3 <br> 4 <br> 5 | reduces / prevents (infectious) disease ; <br> prevent, problems / named problem, with gut ; <br> digest food more, efficiently / easily / quickly ; <br> greater proportion of, food / energy, <br> can contribute to growth ; <br> reduce risk of transmitting, pathogens / named pathogen, to humans; | 2 max | Mark the first two answers only <br> 1 IGNORE illness <br> 2 e.g. diarrhoea <br> 4 ACCEPT faster growth as AW for contribute to growth <br> 4 IGNORE larger chickens <br> 5 ACCEPT 'meat less likely to be infected with bacteria' |
| 3 | (b) | (ii) $1$ <br> 2 <br> 3 | (antibiotic) resistant, pathogens / bacteria ; <br> antibiotics kill useful, bacteria ; <br> idea of: antibiotic passing into human food; | 1 max | 1 ACCEPT microorganisms / microbes <br> 1 IGNORE germs <br> 1 DO NOT CREDIT immune <br> 2 DO NOT CREDIT if any ref to viruses |
|  |  |  | Total | 13 |  |


| Question |  |  | Expected Answers | Marks | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 4 | (a) | (i) | X; | 1 |  |
| 4 | (a) | (ii) | 1 substrate / PABA, and, inhibitor / sulfonamide, similar shape; <br> 2 able to, bind / fit into / block, active site ; <br> 3 (shape) complimentary to active site ; <br> 4 both have, hex / benzene / 6-C, (ring); <br> 5 both have, $\mathrm{NH}_{2}$ / amine; <br> 6 correct ref to a difference between sulfonamide and PABA ; | 3 max | 1 ACCEPT similar structure DO NOT CREDIT same <br> 3 DO NOT CREDIT refs to PABA and sulfonamide being complementary to each other or to the enzyme (alone) <br> 6 e.g. only sulfonamide contains S sulfonamide has 1 more $\mathrm{NH}_{2}$ group sulfonamide has $\mathrm{SONH}_{2}$ but PABA has $\mathrm{N}_{2}$ only PABA has COOH group |
| 4 | (b) | (i) | without inhibitor <br> 1 more, PABA / substrate, molecules enter active site ; <br> 2 more, enzyme substrate complexes / ESCs, formed ; <br> 3 at low concentration not all active sites occupied / at high concentration all active sites occupied ; <br> 4 achieves / reaches, max (turnover) rate / $\mathrm{V}_{\text {max }}$; <br> 5 (at high substrate concentration) enzyme concentration <br> limiting ; | 3 max | 1 ACCEPT more successful collisions between substrate and active site <br> 3 ACCEPT active sites filled / no free active sites DO NOT CREDIT active sites run out <br> 4 ACCEPT 'cannot work any quicker' DO NOT CREDIT 'optimum rate' or 'rate levels off' |


| Question |  |  | Expected Answers | Marks | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 4 | (b) | (ii) | with inhibitor <br> 1 inhibitor / sulfonamide, can, fit / block / bind to / compete for, active site ; <br> 2 (occupies it) for a short time / temporary / reversibly ; <br> 3 fewer active sites available (for substrate) / AW ; <br> 4 (idea of) more substrate reduces chance of inhibitor getting in; | 2 max | 3 ACCEPT substrate can't access active site <br> 4 ACCEPT more ESC formed in context of overcoming inhibition / substrate can out-compete inhibitor |
| 4 | (c) |  | 1 mutation; <br> 2 sulfonamide is selective, agent / pressure; <br> 3 resistant survive / non resistant die; <br> 4 (resistance) allele / gene / mutation, passed to, offspring / next generation ; <br> 5 (happens) over many generations ; <br> 6 AVP; | 4 max | DO NOT CREDIT immune for any mark point <br> 3 IGNORE refs to (survivors) breed / reproduce ; <br> 5 IGNORE refs to time. Look for generations <br> 6 e.g. mutation is, random / spontaneous allele / gene, passed on by, plasmids / horizontal transmission |
| 4 | (d) | (i) | bacteria, killed / destroyed / cannot grow / lyse, in presence of antibiotic ; | 1 | DO NOT CREDIT 'antibiotic works better' or 'there are no bacteria there' or 'bacteria are broken down' |
| 4 | (d) | (ii) | streptomycin ; | 1 | IGNORE '4' as it is the number rather than the name |


| Question |  |  | Expected Answers | Marks | Additional Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 4 | (d) | (iii) | 1 cheap / AW ; <br> 2 (test is) quick to carry out / <br> (deals with several antibiotics) at same time / AW ; <br> 3 (idea of) allowing early treatment of patient; <br> 4 (idea of) compares antibiotics under same conditions ; <br> 5 (correct antibiotic first time) <br> to prevent antibiotic resistance developing ; | 3 max | DO NOT CREDIT responses which simply refer to selecting the best antibiotic <br> 2 DO NOT CREDIT speed of antibiotic action |
| 4 | (e) |  | (new) drugs come from (named) organisms; biodiversity is reducing ; habitats / named habitat, destroyed / lost ; reason for habitat destruction ; | 2 max | ACCEPT plants / animals / fungi / species / etc. <br> ACCEPT deforestation / natural environment lost <br> e.g. global warming <br> logging <br> fuel <br> crops <br> construction / industrialisation <br> mining <br> fishing <br> pollution <br> tourism <br> ACCEPT any other valid reason that will destroy natural habitats but not general statements such as 'human development' or 'business' |
|  |  |  | Total | 20 |  |

